Cover image for Vol. 119 Issue 17

1 September 2013

Volume 119, Issue 17

Pages 3103–3256

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content
    2. You have free access to this content
  2. Original Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program (pages 3106–3112)

      Solveig Hofvind, Giske Ursin, Steinar Tretli, Sofie Sebuødegård and Bjørn Møller

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28174

      In this first mortality analysis based on individual level data from the national screening program in Norway, the authors report a 43% reduction in mortality from breast cancer among screened women compared with nonscreened women. The mortality reduction is likely a result of diagnosing and treating cancers at an early stage.

    2. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status (pages 3113–3122)

      Louis P. Garrison Jr., Deepa Lalla, Melissa Brammer, Joseph B. Babigumira, Bruce Wang and Edith A. Perez

      Article first published online: 17 JUN 2013 | DOI: 10.1002/cncr.28196

      Both immunohistochemistry and fluorescence in situ hybridization analyses of HER2 in breast cancer yield similar rates of concordance (92%) among expert pathologists. The majority of discordant cases can be adjudicated by review and discussion among pathologists.

    3. Chest and Lung Disease
      Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non–small cell lung cancer (pages 3123–3132)

      Anand Shah, Stephen M. Hahn, Robert L. Stetson, Joseph S. Friedberg, Taine T. V. Pechet and David J. Sher

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28131

      Stereotactic body radiation therapy is nearly always the most cost-effective treatment strategy for marginally operable patients who have stage I non–small cell lung cancer. In contrast, for patients with clearly operable disease, lobectomy is the most cost-effective option.

    4. Endocrine Disease
      Marginal treatment benefit in anaplastic thyroid cancer (pages 3133–3139)

      Megan R. Haymart, Mousumi Banerjee, Huiying Yin, Francis Worden and Jennifer J. Griggs

      Article first published online: 9 JUL 2013 | DOI: 10.1002/cncr.28187

      Multimodality management of anaplastic thyroid cancer results in a marginal treatment benefit. The poor overall survival of patients with anaplastic thyroid cancer emphasizes the need for informed patients whose preferences are incorporated into treatment decision-making.

    5. Gastrointestinal Disease
      Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers (pages 3140–3147)

      Amanda I. Phipps, Andrew T. Chan and Shuji Ogino

      Article first published online: 15 JUL 2013 | DOI: 10.1002/cncr.28076

      Colorectal cancer survivors experience an increased risk of subsequent colorectal, small intestinal, lung, endometrial, bladder, stomach, and kidney cancers. Individuals with a history of cancer in the transverse to descending colon have a greater risk of second cancers than those with a prior colorectal cancer at other sites.

    6. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma (pages 3148–3155)

      Lauren E. Colbert, Sarah B. Fisher, Claire W. Hardy, William A. Hall, Burcu Saka, Joseph W. Shelton, Aleksandra V. Petrova, Matthew D. Warren, Brooke G. Pantazides, Khanjan Gandhi, Jeanne Kowalski, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley III, N. Volkan Adsay, Walter J. Curran Jr, Jerome C. Landry, Shishir K. Maithel and David S. Yu

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28144

      Low expression of mixed lineage kinase domain-like protein (MLKL) in patients with resected pancreatic adenocarcinoma is associated with decreased overall survival in those who undergo surgical resection and with decreased recurrence-free and overall survival in the subset of patients receiving adjuvant chemotherapy. MLKL warrants further exploration as a potential prognostic biomarker in patients with resected pancreatic adenocarcinoma.

    7. Prognostic implications of signet ring cell histology in esophageal adenocarcinoma (pages 3156–3161)

      Sai Yendamuri, Miriam Huang, Usha Malhotra, Graham W. Warren, Paul N. Bogner, Chukwumere E. Nwogu, Adrienne Groman and Todd L. Demmy

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28099

      The prognostic role of signet ring cell histology in esophageal cancer is unclear; only a few reports of single-institution series with inconclusive results have been published. In this study, the authors have used the large numbers of patients in the Surveillance, Epidemiology, and End Results (SEER) database to establish the negative prognosis associated with this uncommon variant of esophageal adenocarcinoma.

    8. Head and Neck Disease
      The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer (pages 3162–3169)

      G. Brandon Gunn, J. Matthew Debnam, Clifton D. Fuller, William H. Morrison, Steven J. Frank, Beth M. Beadle, Erich M. Sturgis, Bonnie S. Glisson, Jack Phan, David I. Rosenthal and Adam S. Garden

      Article first published online: 3 JUN 2013 | DOI: 10.1002/cncr.28195

      In a cohort of nearly 1000 patients with oropharyngeal cancer who were staged and irradiated in the modern era, radiographic retropharyngeal lymph node (RPLN) involvement conveys a negative influence on disease recurrence, distant relapse, and patient survival. These benchmark findings highlight the importance of adequate RPLN radiographic assessment, demonstrate why RPLNs are clinically important when formulating therapeutic strategies, and may have implications for design of future clinical studies.

    9. A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma (pages 3170–3176)

      Jin-Gao Li, Xia Yuan, Ling-Ling Zhang, Yi-Qiang Tang, Lan Liu, Xiao-Dan Chen, Xiao-Chang Gong, Gui-Fen Wan, Yu-Lu Liao, Jian-Ming Ye and Fan Ao

      Article first published online: 13 JUN 2013 | DOI: 10.1002/cncr.28201

      A randomized study demonstrated that omitting the lower neck during prophylactic node irradiation would not increase the rate of lower neck nodal relapse. Prophylactic upper neck irradiation is sufficient for patients who have node-negative nasopharyngeal carcinoma.

    10. Hematologic Malignancies
      Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia : Joint experience of the MD Anderson Cancer Center and Duke University Medical Center (pages 3177–3185)

      Lorenzo Falchi, Michael J. Keating, Xuemei Wang, Catherine C. Coombs, Mark C. Lanasa, Sara Strom, William G. Wierda and Alessandra Ferrajoli

      Article first published online: 8 JUL 2013 | DOI: 10.1002/cncr.28030

      African American patients with chronic lymphocytic leukemia present with more unfavorable clinical and biologic characteristics compared with nonblack patients. They also have shorter remission duration after chemoimmunotherapy and shorter event-free and overall survival compared with nonblack patients.

    11. Discipline

      Clinical Trials
      Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer (pages 3186–3194)

      Karen A. Autio, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Ryan D. Stephenson, Susan F. Slovin, Dana E. Rathkopf, Christina Hong, Glenn Heller, Howard I. Scher, Steven M. Larson and Michael J. Morris

      Article first published online: 13 JUN 2013 | DOI: 10.1002/cncr.28103

      Combining bone-seeking radiopharmaceuticals with chemotherapy simultaneously targets the bone stroma and cancer cell to optimize treatment in patients with metastatic castration-resistant prostate cancer. Docetaxel and 153Sm-EDTMP (samarium-153 ethylene diamine tetramethylene phosphonate) were repetitively administered at US Food and Drug Administration-approved doses until disease progression/intolerance. The regimen was found to be well tolerated and effective, supporting combinations of tumor and bone-directed treatments.

    12. Disparities Research
      Ultraviolet index and racial differences in prostate cancer incidence and mortality (pages 3195–3203)

      Glen B. Taksler, David M. Cutler, Edward Giovannucci, Matthew R. Smith and Nancy L. Keating

      Article first published online: 6 JUN 2013 | DOI: 10.1002/cncr.28127

      In counties with more sunshine, the incidence of prostate cancer was reported to be 9% to 23% lower in white men and 10% to 34% lower in black men, with 9% lower racial differences in incidence. Similar patterns were observed for prostate cancer mortality for white men, but not for racial disparities.

    13. Severe lack of comprehension of common prostate health terms among low-income inner-city men (pages 3204–3211)

      Daniel S. Wang, Ashesh B. Jani, Caroline G. Tai, Musu Sesay, Daniel K. Lee, Michael Goodman, Katharina V. Echt, Kerry E. Kilbridge and Viraj A. Master

      Article first published online: 3 JUN 2013 | DOI: 10.1002/cncr.28186

      Lack of comprehension of terms related to the prostate/genitourinary system is pronounced in a low-income patient population and appears to be widespread, including those with higher education. This lack of comprehension potentially limits the ability of patients to participate in shared, informed decision-making and supports a continued need for refined methods of prostate cancer education.

    14. Medical Oncology
      A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor (pages 3212–3218)

      Jennifer A. Chan, Lawrence Blaszkowsky, Keith Stuart, Andrew X. Zhu, Jill Allen, Raymond Wadlow, David P. Ryan, Jeffrey Meyerhardt, Marielle Gonzalez, Eileen Regan, Hui Zheng and Matthew H. Kulke

      Article first published online: 3 JUN 2013 | DOI: 10.1002/cncr.28142

      Temozolomide and everolimus can be safely administered together in patients with advanced pancreatic neuroendocrine tumor, and the combination is associated with an encouraging objective response rate and progression-free survival duration. Future studies evaluating the efficacy of combination therapy compared to treatment with either agent alone are warranted.

    15. Outcomes Research
      Recurrence of high-risk bladder cancer: A population-based analysis (pages 3219–3227)

      Karim Chamie, Mark S. Litwin, Jeffrey C. Bassett, Timothy J. Daskivich, Julie Lai, Jan M. Hanley, Badrinath R. Konety, Christopher S. Saigal and the Urologic Diseases in America Project

      Article first published online: 4 JUN 2013 | DOI: 10.1002/cncr.28147

      Even though most patients with high-grade, non–muscle-invasive bladder cancer do not die of their disease, the vast majority endures the morbidity of recurrence and progression of their cancer. Increasing efforts should be made to minimize the incidence of recurrence and progression of disease.

    16. Pediatric Oncology
      Lymph node management in patients with paratesticular rhabdomyosarcoma : A population-based analysis (pages 3228–3233)

      Nguyen D. Dang, Phuong-Thanh Dang, Jason Samuelian and Arnold C. Paulino

      Article first published online: 6 JUN 2013 | DOI: 10.1002/cncr.28198

      Lymph node dissection is recommended in patients aged >10 years with paratesticular rhabdomyosarcoma. Radiotherapy was found to improve survival in patients with lymph node-positive disease.

    17. Psychosocial Oncology
      Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis (pages 3234–3241)

      Lauren Clevenger, Andrew Schrepf, Koenraad DeGeest, David Bender, Michael Goodheart, Amina Ahmed, Laila Dahmoush, Frank Penedo, Joseph Lucci III, Premal H. Thaker, Luis Mendez, Anil K. Sood, George M. Slavich and Susan K. Lutgendorf

      Article first published online: 24 JUN 2013 | DOI: 10.1002/cncr.28188

      During the first year post-diagnosis, women with ovarian cancer report persistent sleep disturbance. Over time, greater increases in symptoms of depression are associated with increased sleep disturbance, and worsening sleep disturbance is associated with declines in quality of life.

    18. Translational Research
      Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma (pages 3242–3250)

      Malcolm H. Squires III, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley III, Alton B. Farris III and Shishir K. Maithel

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28175

      High ERCC1 tumor expression in resected gastric adenocarcinoma is associated with decreased overall survival in patients receiving chemotherapy, but is associated with increased overall survival in those treated with surgery alone. ERCC1 expression has prognostic value in resected gastric cancer and further investigation of this dichotomous association is warranted.

  3. Correspondence

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence
    5. Erratum
  4. Erratum

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content